PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

NOVAVAX to Present at Stifel Nicolaus Conference

ROCKVILLE, Md., Sept 08, 2010 /PRNewswire via COMTEX/ --

Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Mr. Frederick Driscoll, Chief Financial Officer of Novavax will be presenting at the Stifel Nicolaus Conference. The presentation will take place on Friday, September 17, 2010 at 10:20am local time at the Four Seasons Hotel, Boston, Massachusetts. Mr. Driscoll will provide a company overview, outline its competitive position and characterize Novavax's outlook. A link to the live presentation can be accessed via the Company website at www.novavax.com under Investors/Events. An archive of the presentation will be available after the event on the Novavax website for 30 days.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.